{"id":"rc148-plus-carboplatin-and-paclitaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RC148 blocks the PD-L1 checkpoint, preventing tumor cells from suppressing T-cell activity, thereby restoring anti-tumor immunity. When combined with carboplatin and paclitaxel chemotherapy, the regimen aims to provide both direct cytotoxic effects and enhanced immunological tumor control. This combination approach is designed to improve efficacy in solid tumors resistant to single-agent therapy.","oneSentence":"RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:22.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel)"}]},"trialDetails":[{"nctId":"NCT06883630","phase":"PHASE1","title":"A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2025-03-13","conditions":"Non-Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT07416474","phase":"PHASE3","title":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":574}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RC148 plus Platinum-Based Chemotherapy"],"phase":"phase_3","status":"active","brandName":"RC148 plus Carboplatin and Paclitaxel","genericName":"RC148 plus Carboplatin and Paclitaxel","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RC148 is a PD-L1 inhibitor combined with standard chemotherapy (carboplatin and paclitaxel) to enhance anti-tumor immune response while providing cytotoxic chemotherapy. Used for Advanced or metastatic solid tumors (in combination with carboplatin and paclitaxel).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}